ReviewCurrent oncology reports2026
Antibody-Drug Conjugates in Biliary Tract Cancer: Current Evidence, Emerging Targets, and Future Directions.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewBiliary tract cancer (BTC) is a heterogeneous group of malignancies with limited systemic treatment options and poor prognosis. While immunochemotherapy has become the first-line standard, second-line therapy remains inadequate. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic modality leveraging antigen-specific targeting to deliver potent cytotoxic payloads. This review provides a comprehensive, multi-target appraisal of the ADC landscape in BTC. RECENT
findingsTrastuzumab deruxtecan (T-DXd), supported by DESTINY-PanTumor02 (ORR 22%) and HERB (ORR 36.4%) trials, received 2024 FDA tumor-agnostic approval for HER2-positive solid tumors including BTC. Zanidatamab achieved 41.3% ORR in HERIZON-BTC-01, securing BTC-specific regulatory approval. BL-B01D1, an EGFR×HER3 bispecific ADC, demonstrated preliminary BTC activity (ORR 28.6%) without reported interstitial lung disease in the BTC cohort, though sample size and follow-up remain limited, while its phase III nasopharyngeal carcinoma trial established proof of concept for bispecific ADCs. BL-M05D1 phase I results (ASCO 2026) provided the first clinical evidence for Claudin18.2 ADCs in BTC (ORR 42.5%). Trop2-directed ADCs show theoretical applicability across solid tumors given 69.5% high-expression prevalence, but BTC-specific clinical data are absent. B7-H3 and CD44v5 represent emerging targets with early clinical or preclinical validation. This review provides a unified framework for navigating the rapidly evolving multi-target ADC landscape in BTC. Critical challenges remain, including the absence of phase III randomized trials, tumor heterogeneity, optimal biomarker-guided patient selection, and rational combination strategies with immunotherapy. Standardization of HER2 testing and broader molecular profiling will be essential to realize the clinical potential of ADCs in this historically treatment-refractory disease. Biliary obstruction and hepatic impairment, common in BTC, require ADC-specific pharmacokinetic vigilance and graded toxicity monitoring.
Indexed as
Identifiers
42900315What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.